You are certainly correct in your understanding of what "off label" means.
I think Dr Brekken was most likely just being a little sloppy. He is a research guy, and certainly knows a hell of a lot more than us about what is going on with the drug in these studies. But there is no reason to assume this means he is any more in tune with regulatory terms and such than any average joe.
The simple answer is he just mean "unapproved" and did not realize that "off label" had a different meaning.
Not that I assume anybody can still read this post :-)
JBainseky, great question! Dmitry Gabrilovich has answsers... and I have been wondering about that slide from the very beginning, in combination with slide #38 of 45.
I've written many posts in the past re: Notch Signaling and "all" complexities within this pathway takes on a chain reaction so to speak and PS targeting I say is what they are seeing that is initiating all these chain reactions "for the better" in many indications.
I'll make a bold claim right now, after looking through probably a hundred publications that mention IFNy (Interferon Gamma) and its relation to diabetes. I'll toss out a couple of the links below and have no time now but will try to organize a bunch of them that "may" show this is what Peregrine and KOL's are working towards re: progress in auto-immune diseases...
Now, "Judith Klein-Seetharaman" has worked with Dmitry Gabrilovich... and link below just to verify her work:
Judith Klein
Insulin and IFN gamma receptor studies, Funded by: MATERIA MEDICA, Project Start Date: 01/11/2013 Project End Date: 31/12/2014
There are way too many other publications sources, some which may be better suited to made a good case that PS targeting ( as we know influences MDSC's..etc) and just may be that doorway to the immediate beginning of hundreds of trials/collaborations..etc en route to solutions for the hundreds of auto-immune diseases...
I still do not believe we have seen (as volgoat has mentioned a few times as well)--- the true reasons just yet why we picked up 4 key KOL's--- one being Dmitry Gabrilovich, who happens to be speaking all over the place:
So PS Targeting to MDSC changes to IFNy (Interferon Gamma) that has been proven in dozens of publications to have a correlation, but before the MOA of PS targeting was "better understood" and this better understanding has not been fully disclosedas of yet by Peregrine. Probably using it for leverage I'd say against Big Pharma and to make a deal of a lifetime, because PS targeting is needed for just about everything... including diabetes I believe.